http://vipohity.com/?ed=canadian-viagra-online canadian viagra online
http://vipohity.com/?ed=viagra-from-thailand viagra from thailand
http://abnehmenmitspass.info/?v=afib-and-viagra afib and viagra
- Adequate Size of Enterprise – market capitalization of at least $2 billion – PASS
- Sufficiently Strong Financial Condition – current ratio greater than 2 – FAIL
- Earnings Stability – positive earnings per share for at least 10 straight years – PASS
- Dividend Record – has paid a dividend for at least 10 straight years – PASS
- Earnings Growth – earnings per share has increased by at least 1/3 over the last 10 years using 3 year averages at beginning and end of period – PASS
- Moderate PEmg ratio – PEmg is less than 20 – FAIL
- Moderate Price to Assets – PB ratio is less than 2.5 or PB x PEmg is less than 50 – FAIL
- Sufficiently Strong Financial Condition, Part 1 – current ratio greater than 1.5 – FAIL
- Sufficiently Strong Financial Condition, Part 2 – Debt to Net Current Assets ratio less than 1.1 – FAIL
- Earnings Stability – positive earnings per share for at least 5 years – PASS
- Dividend Record – currently pays a dividend – PASS
- Earnings growth – EPSmg greater than 5 years ago – PASS
chewable viagra online go
|Value Based on 3% Growth||$37|
|Value Based on 0% Growth||$22|
|Market Implied Growth Rate||8.70%|
|Net Current Asset Value (NCAV)||-$7.63|
http://vipohity.com/?ed=xm-radio-viagra xm radio viagra
http://archsimply.pl/?v=is-viagra-legal-in-australia is viagra legal in australia
Earnings Per Share – Modern Graham (Calculating EPSmg)
Colgate-Palmolive has achieved moderate growth over the historical period, but does not meet the requirements of either the Defensive Investor or the Enterprising Investor. For the Defensive Investor, the company’s current ratio is too low and the company is trading at too high a PEmg ratio and a too high PB ratio. For the Enterprising Investor, the company’s current ratio is too low and the company’s debt to net current assets ratio is too high. As a result, the company is too risky for either investor type and may only be considered as a speculative possibility. From a valuation standpoint, the market is implying a growth rate of 8.70%, and while the company has grown its EPSmg (normalized earnings) from $1.54 in 2009 to an estimated $2.54 for 2014, that growth does not quite support the market’s estimation. As a result, the company appears to be overvalued at this time.
What do you think? Is Colgate-Palmolive overvalued? Is the company not suitable for either Defensive Investors or Enterprising Investors? Leave a comment or mention @ModernGraham on Twitter to discuss.
If you like our valuations, why not check out ModernGraham Stocks & Screens? It’s a great way to review the valuations while screening for things like low PE ratio, undervalued companies, etc.!
Disclaimer: The author did not hold a position in Colgate-Palmolive at the time of publication and had no intention of entering into a position within the next 72 hours.
Photo Credit: Andrew Magill